Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Revises Global Sales Strategy; Slashes U.S. Staff, Finds Ways To Retain Chinese Workers

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai Co., Ltd. is unable to meet all of the sales goals it set for its Dramatic Leap Plan, which probably comes as little surprise to most as the Japanese pharma struggles with patent losses of its blockbuster products, approval delays and R&D failures of key compounds. The company is responding by making its U.S. and European operations leaner, at the expense of hundreds of jobs, and stabilizing operations in emerging markets like China, where the company hopes to stem massive employee turnover by bringing staff to Japan for training

You may also be interested in...



Eisai, Morphotek Gain Biologics Manufacturing Capability With New Plant Opening

Eisai gains biologics capability from subsidiary Morphotek’s new biologics manufacturing plant, as Eisai ramps up in emerging markets and transitions itself in a post-Aricept patent world.

Eisai, Morphotek Gain Biologics Manufacturing Capability With New Plant Opening

Eisai gains biologics capability from subsidiary Morphotek’s new biologics manufacturing plant, as Eisai ramps up in emerging markets and transitions itself in a post-Aricept patent world.

Success Hinging On Single Platforms For Kissei, Dainippon Sumitomo, NanoCarrier and Eisai: Japan Earnings Roundup (Part 2)

A look at key products that could determine the year ahead for Japanese pharma.

Related Content

UsernamePublicRestriction

Register

LL021506

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel